startup
Breye Therapeutics
Danish biopharmaceutical company developing oral treatments for early-stage retinal diseases.
- 机会评分
- 90 / 100
- 累计融资
- €67.5 million
- 融资阶段
- Series A
- 成立年份
- unknown
- 地区
- EU
- 阶段
- unknown
八个维度
Company · Problem · Solution · Target Customer · Business Model · Funding · Competitors · Why NowCompany
Clinical-stage biopharma company focused on oral therapies for retinal diseases.
Problem
Late diagnosis and limited treatment options for retinal diseases.
Solution
Oral therapies for early-stage retinal diseases. Improves treatment accessibility.
Target Customer
Patients with retinal diseases. Pharmaceutical partners.
Business Model
Drug development and licensing. Potential partnerships with pharma companies.
Funding
Series A: €67.5 million from Mission BioCapital, Novo Holdings, Sound Bioventures.
Competitors
Novartis, Roche, Allergan
Why Now
Growing aging population. Advances in oral drug delivery for retinal diseases.
来源与 AI 标注
模型 · prompt 版本 · 生成时间 · 来源链接相关项目与同赛道
按赛道继续看相关项目4 家
| 公司 | 赛道 | 评分 |
|---|---|---|
| Aptadir TherapeuticsNovel treatments for genetic conditions | BiotechHealthcare | 90 |
| Sweden’s OmnioAdvanced therapy for chronic wounds | BiotechHealthcare | 75 |
| Mantis人类数字双胞胎 | B2BAIBiotech | 70 |
| Uncommon Therapeutics专注于开发多款十亿级药物的生物技术公司 | HealthcareTherapeuticsBiotech | 70 |
同赛道入口按赛道继续看
数据来自公开渠道与 AI 解读，仅供参考，不构成投资建议。信息可能滞后或有误，决策请以公司官网与官方披露为准。